Validation and Implementation of 3T MRI Research Protocols (VALIDIRM)

The Philips 3T imager installed on the Pavillon Baudot site is an imager dedicated solely to research. It is not located in hospital premises but in INSERM premises for which an authorization for biomedical research has been granted. This equipment is part of the Technical Platform of the UMR 1214 ToNIC whose main objective is the study of the human brain and the main pathologies that affect it.

MRI is an evolving technique, which is used in many research projects. Our technical platform must follow these developments and remain at the cutting edge. One of the essential services of our technical platform is to help set up research protocols and validate acquisition sequences. This development activity is therefore located upstream of research projects involving clinical or fundamental applications. The fact that we can provide our users with a regulatory framework to carry out these development tests for their Research Involving Human Subjects project is a necessity for our research support activity.

This study aims to provide a generic framework to test the feasibility of MRI sequences requested within the framework of protocols, but also to optimize MRI acquisition sequences already in place, to improve image quality and reduce artifacts that can degrade the quality of the images obtained.

In France, there are just over 35 centers with MRI dedicated to research and therefore with a validation protocol allowing them to validate their sequences.

Study Overview

• Status: Recruiting
• Conditions: Magnetic Resonance Imaging
• Intervention / Treatment: Other: Sequences test

Detailed Description

This is a prospective monocentric research on major participants (healthy and patients). The optimization of the sequences will be carried out in an incremental way from one control to the other: for each control, several sequences will be carried out for an acquisition time not exceeding one hour of cumulated acquisition (i.e. one hour and a half including the installation and the delays between the sequences). Each sequence lasts between 5 and 20 minutes.

At the end of the examination, the images obtained will be evaluated jointly by an expert neuroradiologist and a research engineer specialized in image analysis according to the criteria mentioned above. This analysis will make it possible to determine the parameters to be modified to improve image quality and to define the acquisition parameters for the next test.

As soon as a sequence is considered optimal, it will be tested on a small number of healthy controls (≈ 5) to ensure interindividual reproducibility of image quality parameters, and then if necessary in the presence of pathology in a few patients (≈ 5).

• Study Type: Interventional
• Enrollment (Estimated): 230
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Nathalie VAYSSIERE, PHD; Phone Number: +33562746132; Email: nathalie.vayssiere@cnrs.fr
• Study Contact Backup: Name: DAGNAC, PHD; Phone Number: +33562746122; Email: helene.gros@inserm.fr

Study Locations

• France
  • Toulouse, France, 31000
    • Recruiting
    • UMR 1214 ToNIC INSERM
    • Contact: PAYOUX Pierre; Email: pierre.payoux@inserm.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Male or female, 18 years of age or older
• Ability to cooperate and remain motionless for up to 1 hour (and lying down for 1.5 hours)
• Ability to understand the instructions given
• Subject who has given written and informed consent prior to any examination required by the research)
• Subject affiliated to a social security system or benefiting from an equivalent system

Exclusion Criteria:

• Persons deprived of liberty by judicial or administrative decision
• Psychiatric disorders, disorders of cognitive functions, not allowing the realization of the MRI
• Protected adults (subject to a measure of legal protection) or unable to express their consent
• Subject with Contraindications to MRI

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Sequence validation; This research aims to provide a generic framework to test the feasibility of MRI sequences requested as part of protocols, but also to optimize MRI acquisition sequences already in place, to improve image quality and reduce artifacts that can degrade the quality of images obtained.	Other: Sequences test; the realization of preliminary acquisitions to validate the feasibility of clinical or cognitive research protocols

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
in general	optimization of parameters acquisition in order to suppress artefact	at the end of studies ((i.e. one hour and a half including the installation and the delays between the sequences). Each sequence lasts between 5 and 20 minutes.

Collaborators and Investigators

• Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
• Investigators: Principal Investigator: Pierre PAYOUX, Pr, Inserm: UMR 1214 ToNIC

Study record dates

Study Major Dates

• Study Start (Actual): May 12, 2021
• Primary Completion (Estimated): May 12, 2027
• Study Completion (Estimated): May 12, 2027

Study Registration Dates

• First Submitted: April 7, 2021
• First Submitted That Met QC Criteria: April 29, 2021
• First Posted (Actual): April 30, 2021

Study Record Updates

• Last Update Posted (Actual): February 18, 2026
• Last Update Submitted That Met QC Criteria: February 13, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: C20-28

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No